loading page

Refractory Pediatric Acute Myeloid Leukemia expressing NUP98-NSD1 Fusion Gene Conquered by Venetoclax and DCAG
  • +8
  • Hongbo Chen,
  • Huan Xu,
  • Hui Yu,
  • jiawei xu,
  • Xiaoyan Wu,
  • Fen Zhou,
  • Shuo Tang,
  • Xingxing Feng,
  • Quan Luo,
  • Bingyu Zhang,
  • Runming Jin
Hongbo Chen
Wuhan Union Hospital

Corresponding Author:[email protected]

Author Profile
Huan Xu
Wuhan Union Hospital
Author Profile
Hui Yu
Wuhan Union Hospital
Author Profile
jiawei xu
Wuhan Union Hospital
Author Profile
Xiaoyan Wu
Wuhan Union Hospital
Author Profile
Fen Zhou
Wuhan Union Hospital
Author Profile
Shuo Tang
Wuhan Union Hospital
Author Profile
Xingxing Feng
Wuhan Union Hospital
Author Profile
Quan Luo
Wuhan Union Hospital
Author Profile
Bingyu Zhang
Wuhan Union Hospital
Author Profile
Runming Jin
Wuhan Union Hospital
Author Profile

Abstract

Pediatric AML with NUP98-NSD1 fusion defines a high-risk subset with a low remission and high relapse rates. There are a few studies on successful treatment of high-risk AML expressing NUP98-NSD1. We report a refractory pediatric case who received successful treatment with Bcl-2 inhibitor, venetoclax plus DCAG chemotherapy followed by HSCT, after two failure courses of conventional chemotherapies. Our case suggests that the combination of venetoclax and DCAG chemotherapy may be an effective salvage strategy to refractory AML with NUP98-NSD1. More studies and clinical trials should focus on the synergistic effect of Bcl-2 inhibitors and hypomethylation agents, especially in pediatric AML.